Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 423

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 4
Chunk 423
---
&D tax credit carryforwards to offset future taxable income and tax liabilities.

Risks Related to Our Common Stock 

An active, liquid and orderly trading market may not develop for our common stock and as a result it may be difficult for you to sell your shares of our common stock. 

Prior to our IPO in April 2020, there was no public market for shares of our common stock. Although our common stock is currently listed on the Nasdaq Global Market, we cannot assure you that an active trading market for our shares will develop or be sustained. In the absence of an active trading market for our common stock, investors may not be able to sell their shares of common stock without depressing the market price for the common stock, or may not be able to sell the shares at all. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and 

79

may impair our ability to enter into collaborations or acquire other companies or technologies using our shares as consideration. 

Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. 

We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:

■variations in the level of expense related to the ongoing development of our product candidates and preclinical and clinical development programs; 

■results of preclinical studies and ongoing and future clinical trials, or the addition or termination of clinical trials or funding support by us, or current or future collaborators or licensing partners; 

■our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements; 

■any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; 

■additions and departures of key personnel; 

■strategic decisions by us, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; 

■if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates; 

■regulatory developments affecting our product candidates; and

■general economic conditions, including as a result of bank failures, as well as economic conditions specifically affecting the biopharmaceutical industry. 

If our quarterly operating results fall below the expectations of investors or securities